Tigilanol tiglate (USAN;[1] ), sold under the brand name Stelfonta is a medication used to treat dogs with non-metastatic, skin-based (cutaneous) mast cell tumors (MCTs).

[3] In 2022, the Wender group reported an efficient semi-synthesis of tigilanol tiglate from phorbol (12% overall yield over 12 steps).

[6] It was discovered through an automated screening process of natural products by selecting increasingly purified fractions of plant extracts, based on their ability to produce the desired activity profile.

Tigilanol tiglate is a phorbol ester which, along with other related compounds, acts as a protein kinase C regulator.

[7] The initial lead came from observation that marsupials found the seed of Fontainea picrosperma (blushwood) unpalatable due to an inflammatory chemical present in reasonably high concentrations.